Loading...
•
Mar 31, 2021
Innoviva Q1 2021 Earnings Report
Reported financial results with royalty revenues growing 8% year over year, positively impacted by non-recurring items.
Key Takeaways
Innoviva reported its Q1 2021 financial results, highlighting an 8% year-over-year growth in royalty revenues, which was positively impacted by non-recurring items such as prior-period adjustments and favorable foreign exchange rates. The company strategically deployed capital in healthcare companies and resolved its arbitration with Theravance BioPharma.
Royalty revenues increased by 8% year-over-year, benefiting from non-recurring items.
RELVAR®/BREO® ELLIPTA® global net sales showed modest growth compared to Q1 2020, with a 5% increase in the U.S. and a 2% decrease in non-U.S. sales.
ANORO® ELLIPTA® global net sales increased by 7% in Q1 2021, driven by an 8% increase in U.S. sales and a 5% increase in non-U.S. sales.
TRELEGY® ELLIPTA® global net sales increased by 37% in Q1 2021, attributed to strong volume growth and a favorable prior-period adjustment in the U.S.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...